AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (Previously Presented). A liposome that includes a drug intended for the therapy and/or diagnosis, comprising as membrane constituents [1] a basic compound, [2] an acidic compound which is a phosphoric acid monoester derivative, or a compound having a carboxyl group or its salt, and [3] a liposome membrane constituent other than [1] and [2], that is accumulated at a diseased site at pH 5 to 7, wherein a molar ratio of said basic compound is 1 to 30 mol% of total liposome membrane constituents and a molar ratio of said acidic compound is 0.5 to 30 mol% of total liposome membrane constituents.

Claims 2-3 (Canceled).

Claim 4 (Currently Amended). The liposome according to claim 1, wherein said basic compound is represented by any one of the following Formulae 1 to 4[[.]]:



Formula 1

~~(in~~ wherein Formula 1, A represents an aromatic ring[[.]]; R^1 and R^2 represent an alkyl group or alkenyl group having 10 to 25 carbon atoms, where R^1 and R^2 may be the same or different[[.]]; ~~X1~~ X^1 and ~~X2~~ X^2 represent -O, -S-, -COO-, -OCO-, -CONH- or NHCO-, where ~~X1~~ X^1 and ~~X2~~ X^2 may be the same or different[[.]]; m is 0 or 1, and n is 0 or an integer of 1 to 6[[.)]];



Formula 2

~~(in~~ wherein Formula 2, R^3 represents hydrogen or an alkyl group or alkenyl group having 1 to 8 carbon atoms[[.]]; R^5 and R^6 represent hydrogen, or an alkyl group or alkenyl group having 1 to 25 carbon atoms, [[(]]except for the case where both R^5 and R^6 are hydrogen atoms[[)]], where R^5 and R^6 may be the same or different[[.]]; ~~X3~~ X^3 represents -O- or –S-[[.]]; p is 0 or 1, and q is 0 or an integer of 1 to 10[[).]];



Formula 3



Formula 4

Claim 5 (Previously Presented). The liposome according to claim 1, wherein said basic compound is a basic compound having a quaternary amine or a tertiary amine.

Claim 6 (Currently Amended). The liposome according to claim 1, wherein said basic compound is selected from the group consisting of the following Formulae 5 and 6[[.]]:



Formula 5

(~~in~~ wherein Formula 5, R^7 and R^8 represent an alkyl group or alkenyl group having 1 to 8 carbon atoms, where R^7 and R^8 may be the same or different[[.]]; ~~X4~~ X^4 and ~~X5~~ X^5 represent -O- or –OCO-, where ~~X4~~ X^4 and ~~X5~~ X^5 may be the same or different[[.]]; R^9 and R^{10} represent an alkyl group or alkenyl group having 10 to 20 carbon atoms, where R^9 and R^{10} represent an alkyl group or alkenyl group having 10 to 20 carbon atoms, where R^9 or R^{10} may be the same or different[[.]]; t is an integer of 1 to 6[[.)]];



Formula 6

~~(in~~ wherein Formula 6, R^7, R^8 and R^9 represent an alkyl group or alkenyl group having 1 to 8 carbon atoms, where R^7, R^8 and R^9 may be the same or different[[.]]; ~~X4~~ X^4 and ~~X5~~ X^5 represent -O- or -OCO-, where X4 and X5 may be the same or different[[.]]; R^9 and R^{10} may be the same or different[[.]]; t is an integer of 1 to 6[[.)]].

Claim 7 (Previously Presented). The liposome according to claim 1, wherein said phosphoric acid monoester derivative is selected from predonisolone phosphate, riboflavin phosphate, and phosphatidic acid.

Claim 8 (Previously Presented). The liposome according to claim 1, wherein said compound having a carboxyl group or its salt, is a fatty acid.

Claim 9 (Currently Amended). The liposome according to claim 8, wherein said fatty acid is oleic acid, stearic acid, palmitic acid, or myristic acid.

Claim 10 (Previously Presented). The liposome according to claim 1, wherein the liposome membrane constituent other than [1] and [2], is phospholipids or its derivative, and/or sterol or its derivative.

Claim 11 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is an antic-cancer agent, an antibiotic, an enzyme agent, an enzyme inhibitor, an antioxidant, a lipid uptake inhibitor, a hormone agent, an anti-inflammatory agent, a steroid agent, a vasodilator, an angiotensin converting enzyme inhibitor, an angiotensin receptor

antagonist, a growth/migration inhibitor for smooth muscle cells, a platelet aggregation inhibitor, an anticoagulant, a chemical mediator releasing inhibitor, a vascular endothelial cell growth or suppressing agent, an aldose reductase inhibitor, a mesangium cell growth inhibitor, a lipoxygenase inhibitor, an immunosuppressor, an immunoactivator, an antiviral agent, a Maillard reaction inhibitor, an amyloidosis inhibitor, an NOS inhibitor, an AGEs inhibitor, or a radical scavenger.

Claim 12 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is a nucleic acid, a polynucleotide, a gene and its analogue.

Claim 13 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is glycosaminoglycan and its derivative.

Claim 14 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is oligo- and/or polysaccharide, and derivative thereof.

Claim 15 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is protein or peptide.

Claim 16 (Previously Presented). The liposome according to claim 1, wherein said drug intended for the therapy and/or diagnosis is an intracorporeal diagnostic

drug such as an X-ray contrasting medium, a radiolabeled nuclear medicinal diagnostic drug, or a nuclear magnetic resonance diagnostic drug for diagnosis.

Claim 17 (Original). A method of increasing a ratio of accumulation of liposome at a diseased site, comprising adding to a liposome membrane constituent including a drug for a therapy and/or diagnosis [1] a basic compound and [2] an acidic compound, which is a phosphoric acid monoester derivative, or a compound having a carboxyl group or its salt, such that a ratio of an adsorption amount of chondroitin sulfate C to liposome in a phosphate buffer of pH 6.5 to that in a phosphate buffer of pH 7.4 is at least 1.5.

Claim 18 (Original). A method for the therapy and/or diagnosis, comprising administering to an animal including a human a liposome including a drug intended for the therapy and/or diagnosis comprising as liposome membrane constituents [1] a basic compound, [2] an acidic compound, which is a phosphoric acid monoester derivative, or a compound having a carboxyl group or its salt, and [3] a liposome membrane constituent other than [1] and [2] to accumulate it at a diseased site at a pH of 5 to 7.

Claim 19 (Canceled).

Claim 20 (New): A liposome that includes a drug intended for the therapy and/or diagnosis, comprising as membrane constituents [1] a basic compound, [2] an acidic compound which is a phosphoric acid monoester derivative, or a compound

having a carboxyl group or its salt, and [3] a liposome membrane constituent other than [1] and [2], wherein a ratio of an adsorption amount of chondroitin sulfate C to the liposome in a phosphate buffer of pH 6.5 to that in a phosphate buffer of pH 7.4 is at least 1.5.